Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 0.71 |
| ▸ | PPARA | Q07869 | 9/20 | 0.71 |
| ▸ | PPARG | P37231 | 5/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548952 | 0.94 | PPARD (0.71) | PPARDPPARAPPARG | |
| SCHEMBL5508795 | 0.92 | PPARD (0.60) | PPARDPPARAPPARG | |
| SCHEMBL4110321 | 0.91 | PPARD (0.82) | PPARDPPARAPPARG | |
| SCHEMBL5511651 | 0.89 | PPARD (0.71) | PPARDPPARAPPARG | |
| SCHEMBL5508820 | 0.86 | PPARD (0.60) | PPARDPPARAPPARG | |
| SCHEMBL5519825 | 0.86 | PPARD (0.71) | PPARDPPARAPPARG | |
| SCHEMBL5505976 | 0.86 | PPARD (0.62) | PPARDPPARAPPARG | |
| SCHEMBL4124232 | 0.84 | PPARD (0.70) | PPARDPPARAPPARG | |
| SCHEMBL5511310 | 0.84 | PPARD (0.50) | PPARDPPARAPPARG | |
| SCHEMBL1602178 | 0.83 | PPARD (1.00) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | AUERBACH BRUCE J (US) | 2005-07-14 | — | — | US | claimed |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | AUERBACH BRUCE J (US) | 2005-05-26 | — | — | US | claimed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1994015-B1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | FELSTEAD STEPHEN JOHN | 2010-10-21 | — | — | US | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1994015-A1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070088069-A1 | Novel imidazoles | WARNER-LAMBERT COMPANY LLC | 2007-04-19 | — | — | US | disclosed |
| US-6964983-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-15 | — | — | US | disclosed |
| US-6939875-B2 | Carbocyclic oxy sulfides such as [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-acetic acid, used to control peroxisome proliferator activated receptors (PPAR), for prophylaxis of metabolic disorders | WARNER-LAMBERT COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | AUERBACH BRUCE J (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | AUERBACH BRUCE J (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1494989-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | PPARD 208/4885PPARA 258/4885PPARG 430/4885 |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885PPARG 3/4885 |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885PPARG 3/4885 |
| US-20070088069-A1 | Novel imidazoles | APOB, LIPC, LIPG | PPARD 175/4885PPARA 300/4885PPARG 226/4885 |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | CETP, CCR5, MTTP | PPARD 424/4885PPARA 423/4885PPARG 736/4885 |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.